纽约–(BUSINESS WIRE)–(美国商业资讯)– 全球链上风险领域的领导者Elliptic今日宣布推出Elliptic，让每一位一线执法人员和政府工作人员都能直接评估加密货币线索的优先级。 如今，从街头巡逻到案件侦查，加密货币已涉及执法工作的各个环节。无论是在嫌疑人手机中、ATM诈骗受害者的收据上，还是在搜查车辆或随身衣袋时，抑或在药物过量事件、逮捕或查扣现场发现加密货币地址，Pulse都能迅速提供准确的资金情况摘要，为执法人员指明调查切入点。 执法人员只需输入任何疑似钱包地址或交易哈希值的信息，Pulse即可加以识别，对结果进行推理分析，并以通俗易懂的语言生成摘要，帮助执法人员当场判断是否需要将案件移交进一步处理。 如果案件需要深入调查，执法人员只需点击一下，即可将完整分析连同证据一并转交。刑事侦查部门收到的材料包括摘要、分析依据以及执法人员的现场记录，均附有案件编号。这些信息可直接导入Elliptic Lens进行筛查、导入Investigator开展取证追踪，也可接入团队现有的工作流程。接手案件的侦查人员同样无需精通区块链，因为Pulse已完成相关分析。 Ellip
Month: September 2026
NEW YORK–(BUSINESS WIRE)–Elliptic, leader mondial de la gestion des risques on-chain, annonce aujourd’hui le lancement de Pulse. Cette solution permet aux agents des forces de l’ordre et aux agents des services gouvernementaux de prioriser directement les pistes d’enquête liées aux cryptomonnaies. Les cryptomonnaies concernent désormais tous les échelons des forces de l’ordre, de l’agent de patrouille sur le terrain à l’enquêteur chargé du dossier. Pulse fournit à chacun d’eux une synthèse fi
NEW YORK–(BUSINESS WIRE)–Elliptic, der weltweit führende Anbieter im Bereich On-Chain-Risiken, hat heute Pulse auf den Markt gebracht. Mit Pulse liegt die Priorisierung von Krypto-Hinweisen direkt in den Händen jedes Beamten an vorderster Front bei Strafverfolgungsbehörden und Behörden. Kryptowährungen betreffen mittlerweile jeden Bereich der Strafverfolgung – vom Streifenpolizisten auf der Straße bis hin zum Ermittler, der mit der Aufklärung eines Falles betraut ist. Pulse liefert jedem von
NOVA YORK–(BUSINESS WIRE)–A Elliptic, líder global em risco on-chain, lançou hoje o Pulse. O Pulse coloca a priorização de leads de criptomoedas diretamente nas mãos de cada autoridade governamental ou de aplicação da lei que atua na linha de frente. As criptomoedas agora afetam todas as áreas de aplicação da lei, de policiais nas ruas a detetives designados a investigar o caso. O Pulse dá a cada um deles um resumo financeiro rápido e preciso, e um ponto de partida: se é um endereço de cripto
What if measuring your pharmaceutical products’ environmental footprints could open doors that price alone never will? Clinical outcomes and cost have always decided whether a new pharmaceutical product — be it a vaccine, weight loss drug, or chemotherapy — reaches patients. That’s not going to change, nor should it. But lately, the institutions that decide which therapies make it to market are asking a new question: What impact does this therapy have on the environment? They want medicines built with raw materials that have a low environmental impact and that won’t become a regulatory liability in the future. They’re looking for therapies that leave less behind at end of life, and whose footprint a company can prove with data.
Including the environmental impact of therapies has never been a requirement, voluntary or mandatory, for market access bids, but this could be changing. For pharmaceutical companies ready to get ahead of that shift, a new standard for Life Cycle Assessments (LCAs) and Product Carbon Footprints (PCFs) is fast becoming one of the most powerful tools for winning market access.
Long considered the touchstone for measuring the environmental impacts of products as varied as food, furniture, concrete, and glass, LCAs give companies and their suppliers a clear, data-driven understanding of environmental hotspots across manufacturing and supply chains, while PCFs — an LCA focused solely on a product’s climate change impact — help companies drill down into their greenhouse gas (GHG) emissions. Yet despite their proven value elsewhere, the use of LCAs and PCFs in the pharmaceutical industry has never been standardized until now.
Introducing PAS 2090:2025, Pharmaceutical products – Product category rules for environmental life cycle assessments, the first internationally applicable framework for conducting both LCA and PCF assessments of pharmaceutical products. Here, we explore how PAS 2090-aligned LCAs and PCFs help pharma companies make sustainable decisions, reduce risk, and lead within a climate-conscious market.
Introduction of PAS 2090:2025
Released in November 2025, PAS 2090 reflects considerable cross-sector collaboration. The standard was developed by the British Standards Institution (BSI) with co-sponsorship from NHS England, the Office for Life Sciences (UK), and the Pharmaceutical LCA Consortium, using extensive global stakeholder input with insights from academia and healthcare. Over 475 stakeholders from 35 countries participated via a digital engagement hub, with more than 400 public comments submitted during the public consultation period.
In terms of functional specifications, PAS 2090 covers “pharmaceutical products intended for human use and the pharmaceutical product life cycle, including the drug substance, formulation, device (if applicable), packaging, distribution, patient use and end of product life.” It guides the process of assessing the environmental impact of pharmaceutical products from “cradle,” as in the sourcing of raw materials, up until the product’s final disposal, or “grave,” at end of life.
Though still in a nascent stage, the European Federation of Pharmaceutical Industries and Associations recognizes PAS 2090 as the “first publicly available specification to establish harmonized Product Category Rules (PCR) for conducting LCAs and PCFs of pharmaceutical products.” By adopting one unified standard, companies can generate aligned assessments without producing different analyses for each healthcare payer, thus reducing workload and improving trust in the data for payers and health tech evaluators. We’re looking at a new era of transparency and comparability ushered in by this new, publicly available specification.
Growing Importance in Market Access
The details of LCA standardization across the global pharmaceutical industry will need more time to be carved out completely. But already major health systems including NHS England, The National Institute for Health and Care Excellence, and the Norwegian Hospital Procurement Trust are increasingly looking at integrating environmental criteria into therapy evaluation and purchasing. As a result, therapies supported by credible LCA and PCF data can gain a competitive advantage in market access and tendering. (Tender, or tendering, refers to a formal process by which pharmaceutical therapies and healthcare technologies are procured.)
Consider the National Institute for Health and Care Excellence (NICE), which sits at the gateway to the UK public healthcare market. Its rigorous assessments of a health technology’s safety, clinical effectiveness, and affordability directly shape what the National Health Service (NHS) will fund. Now, NICE is exploring whether environmental impact evidence could join that submission, and whether it would be structured much like the clinical and cost-effectiveness data producers must submit as part of their market access bids. Their Health Technology Assessment (HTA) Innovation Laboratory is assessing what the evidence might look like, and looks to PAS 2090 as the standard that can provide a credible, consistent framework.
Healthcare payers are beginning to evaluate the environmental footprint of the therapies they buy. In crowded therapeutic categories, that creates an opening. Early adopters that showcase credible LCA and PCF data can differentiate their products and demonstrate the exact kind of leadership that resonates in a climate-conscious world. This is especially powerful for small- and medium-sized enterprises (SMEs) that can’t always win on price. Environmental performance gives them a different way to compete — one built on integrity and innovation rather than a race to the bottom on cost. And there’s now evidence that it works.
In a case study conducted with the Norwegian Hospital Procurement Trust (Sykehusinnkjøp), researchers found that prioritizing environmental criteria paid off in the long run through a more secure supply chain and a shift away from non-renewable materials. Rewarding environmental performance over price raised public spending in the short term, but it kept suppliers in the market and reduced medicine shortages over time. Most tellingly, in the Trust’s anti-infectives tender, environmental criteria brought suppliers back into contention — 8 of 21 contracts went to bids that were not the lowest priced. In other words, by showcasing their products’ reduced environmental impact along with assessments of supply chain risks and hotspots, some companies are returning with competitive bids that not too long ago may have had little hope of winning.
Operational and Supply Chain Benefits
LCAs also offer a number of benefits for improved business operations and overall supply chain efficiency. By pinpointing energy intensive steps and materials with disproportionate environmental impacts, LCAs provide companies with a better understanding of their critical supply chain vulnerabilities. And by tending to these hotspots strategically, organizations can reduce environmental risk, optimize performance, and lower long-term operational costs.
A few highlighted benefits coming from the use of LCA in support of pharmaceutical product development include:
- Process optimization, spotting materials and supply chain areas with outsized environmental impact.
- Minimizing waste and harmful emissions across the product’s life cycle for environmental and regulatory gains.
- Resource-efficient product design, resulting in lower material and energy use and decreased production costs.
- Enhanced supply chain resilience, as LCA insights help address process and supply chain vulnerabilities before they disrupt operations.
Future-proofing for 2030 and Beyond
A decade from now, environmental data won’t be a differentiator — it will be an expectation. Climate pressures and resource scarcity are already reshaping operational risk and cost, and global health systems are steadily raising the bar for the environmental evidence they require from suppliers.
Companies that adopt PAS 2090-aligned LCAs today are doing more than reducing impact. They’re future-proofing, building the transparency and market credibility that tomorrow’s industry will demand. The head start starts now.
Ready to Strengthen Your Environmental Strategy?
Our LCA experts help pharmaceutical companies and suppliers generate high quality, PAS 2090 aligned assessments that unlock strategic, operational, and market access advantages.
Contact us to get started with an LCA or PCF that elevates your sustainability and competitive position.
About the Author
Millicent Gabriel is a Life Cycle Associate and sustainability consultant with SCS Consulting Services, bridging life sciences and environmental stewardship. She holds an MS from Northeastern University in Cell and Tissue Engineering and a BS in Chemical Engineering. With a five-year background in the pharmaceutical sector, she combines expertise in Life Cycle Assessments (LCA) and Product Carbon Footprints (PCF) to help empower clients to make smart decisions for emission reductions. She also focuses on Extended Producer Responsibility (EPR) and end-of-life management of products and packaging.
DOHA, Qatar–(BUSINESS WIRE)–Doha Debates, de Qatar Foundation, estrenó una nueva temporada de Doha Debates Podcast, con 20 episodios que se publicarán semanalmente hasta el 16 de febrero de 2027. La serie reúne a destacados pensadores de todo el mundo para analizar algunos de los temas más complejos y relevantes de la actualidad. Los nuevos episodios profundizan en cuestiones planteadas en los principales debates y foros públicos de Doha Debates mediante conversaciones extensas y reflexivas.
EDISON, N.J.–(BUSINESS WIRE)– #CollaborativeSurgicalIntelligence–Redefine Surgery, a medical technology company building physical AI for surgery, today announced the closing of an oversubscribed pre-seed financing round, bringing total capital raised to $10 million. Backed predominantly by surgeon investors, the financing will support continued development of the company’s surgical intelligence platform as it advances toward commercialization. The financing announcement follows Wednesday’s announcement by Catalyst OrthoScience
NUEVA YORK–(BUSINESS WIRE)–Elliptic, líder mundial en el riesgo en cadena, lanzó hoy Pulse. Pulse pone la priorización de pistas sobre criptomonedas directamente en manos de cada agente de primera línea de las fuerzas de seguridad y del gobierno. Las criptomonedas ahora están presentes en todos los ámbitos de las fuerzas de seguridad, desde los agentes que patrullan las calles hasta el detective asignado a la investigación de un caso. Pulse le brinda a cada uno de ellos un resumen financiero
لندن–(BUSINESS WIRE)–أعلنت شركة HeadFirst Global، الرائدة في مجال تنظيم العمل، اليوم أنها ستصبح Vertage، حيث تقوم ببناء منصة تكنولوجية عالمية تقوم بتنسيق المزيج المناسب من المواهب الخبيرة ووكلاء الذكاء الاصطناعي بشكل ديناميكي لتحقيق نتائج العمل التي تحتاجها المؤسسات.يتناول هذا البيان الصحفي الوسائط المتعددة. يمكنك الاطلاع على البيان كاملاً هنا: https://www.businesswire.com/news/home/20260923352314/ar/Edzard Overbeek، الرئيس التنفيذي للمجموعة في Vertageتجمع المجموعة -التي تبلغ قيمتها 10 مليارات
LONDRA–(BUSINESS WIRE)–HeadFirst Global, un leader nel settore dell’orchestrazione del lavoro, oggi ha annunciato che diventerà Vertage, mentre sviluppa una piattaforma tecnologica globale in grado di selezionare dinamicamente la giusta combinazione ideale di talenti esperti e agenti IA per offrire alle aziende i risultati operativi di cui queste hanno bisogno. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono o